Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Current Quarter	$0.15	Next Quarter	$0.19
Current Year	$0.71	Next Year	$NA
QoQ Growth	+26.7%	YoY Growth	NaN%
3Y EPS CAGR	+17.6%	Target Price	$6.25
Consensus	Buy	Upside	+61.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORMP	$3.88	+2.37%	149.67K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ORMP	$3.88	+2.4%	149.67K
3
4
5
6

ORMP

ORMP

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Oramed Pharmaceuticals Inc. Data in Excel

Get Oramed Pharmaceuticals Inc. Data in Excel